AzTrials
AzTrials

Sleep Apnea, ObstructiveNCT02832414

Effectiveness of an Intensive Weight Loss Program for Obstructive Sleep Apnea Syndrome (OSAS) Treatment.

A study testing Intensive weight loss program in people with Sleep Apnea, Obstructive and Obesity, run by Hospital Universitari de Bellvitge at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine if a lifestyle change program for obese patients who are already receiving continuous positive airway pressure (CPAP) treatment can achieve weight loss and overall improvement of obstructive sleep apnea syndrome (OSAS). Read more about this study

Who is it for?
Ages 25 to 60 years
Conditions the study is for
Sleep Apnea, Obstructive, Obesity
What is being tested?
Intensive weight loss program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
42 participants
Where
1 siteSpain
Study dates
Jul 2016to Jun 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients who have been diagnosed with severe obstructive sleep apnea syndrome (AHI > 30) and are already receiving CPAP treatment (since at least 6 months), who have class I and class II obesity (body mass index (BMI) >= 30 kg /m2 y <= 40 kg/m2).

Who cannot join

  • diseases that limit exercising or diet,
  • cognitive impairment that prevents understanding the program,
  • psychiatric disorders,
  • severe diseases, major cardiovascular disease,
  • clinical instability within the previous month,
  • prior bariatric surgery,
  • refusal to participate in the study,
  • participation in another clinical trial.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Hospital Universitari de Bellvitge

    L'Hospitalet de Llobregat, Barcelona

Other trials in Spain

About this study

The purpose of this study is to determine if a lifestyle change program for obese patients who are already receiving continuous positive airway pressure (CPAP) treatment can achieve weight loss and overall improvement of obstructive sleep apnea syndrome (OSAS).

Read the detailed description

Calculating the sample size:

The primary endpoint is the reduction of final apnea-hypopnea index (AHI) with respect to baseline. Assuming an alpha level of 0.05 and a bilateral approach to have 80% statistical power, the investigators estimate a final sample size of 42 patients is required to detect a 15 point difference in AHI between the intervention and control groups (clinically relevant difference), with a standard deviation of 15 (visit 9) and accounting for a 25% rate of attrition. Balanced groups are expected.

Lifestyle Change Program:

This will consist of a 3-month long first stage of intensive diet and progressive exercise with visits to a nutritionist every 15 days. A second stage will last until completion of one year, with a diet that is progressively higher in calories, more intense exercise, appointments that are spaced further apart and are alternatively individual and group visits.

Diet First stage: 12 weeks

  1. first 15 days: Very low calorie diet. A diet that is very low in calories will be started (600-800 kilocalories (Kcal), based on gender and level of physical activity) with low calorie shakes. Supplementing the diet with herbal teas and sugar-free beverages will be allowed.
  2. Up to week 12: 1200 Kcal diet with a low calorie shake replacing the evening meal. Exercising begins.

At each visit the nutritionist will provide advice on diet and lifestyle, with special emphasis on diet and exercise. Visits to the nutritionist will be every 15 days. The first two will be group visits and afterwards individual visits will alternate with group visits every 15 days (see chart below). On alternate weeks a nurse will phone the patients to remind them of the diet's basic guidelines.

Every session will last from 60 to 90 minutes and will be conducted by a nutritionist. The subjects will be asked to keep a 3 day log of what they eat at the start of the study and at and at each visit in order to estimate nutrient intake. Every patient will be provided with information about the entire program and the different group and individual sessions with the nutritionist. At each visit the participants will be weighed and asked for the results of the tests for ketones in the urine once a week. The nutritionist will follow compliance with the program and monitor for potential adverse events at each visit.

Second stage: from 12 weeks to 1 year A 1200-1500 Kcal diet will be maintained, based on gender and level of physical activity, without the low calorie shake. Calorie intake will be based on a Mediterranean diet, recommending a maximum fat intake of 30% and high consumption of fruit, vegetables, poultry, fish, lean meat and legumes, in accordance with the recommendations of the American Dietetic Association.

Visits to the nutritionist will take place monthly from the third to the sixth month and every 3 months from the sixth to the 12th month, with individual visits alternating with group visits (see chart below).

They will also receive a phone call every month, alternating with the visits, which will be made by the company that supplies the CPAP equipment.

Exercise

The following exercise program will be recommended:

  1. Walk briskly for at least 50-60 minutes at a time, at least 3 times per week, ideally 5 days a week. Exercising is to increase gradually, starting with 10 minute periods, repeated on the same day and that will be gradually increased as tolerated by the patient. Heart rate will be used to monitor exercise intensity, it is recommended that aerobic exercise be performed at 70-80% of maximum heart rate. (Lung (2014) 192:175-184).
  2. Every workout session will consist of stretching, 5-10' of warm up (50-60% of maximum heart rate (HR)), 40-50' of aerobic exercise performed at 70-80% of maximum HR and 5-10' of cool down (50-60% of maximum HR). The table for stretches to be performed before and after exercising will be given in writing. The patients will receive information on how to perform the exercises and everything related to it at a group training session before the start of the program.
  3. To encourage exercise, the chance to perform it at least once a week in guided groups, in the patient's town of residence, will be offered.

Follow up:

  1. On each visit to the nutritionist, in addition to data regarding adherence to the diet, data regarding adherence to the exercise program will be recorded: number of sessions and minutes/week.
  2. During the group sessions, the nurse in charge of the study will respond any questions that may arise concerning the development of the exercise program.
  3. Patients who have a smart phone will also be able to record their activity using an app (Endomondo) , which the nurse and the nutritionist will be able to access (see the section on variables). In addition to tracking their own exercise history, patients will be able to see that of the other patients in the study if they opt voluntarily to choose that option.

If any musculoskeletal complaints that are deemed relevant should occur during the course of the exercise program, the Rehabilitation Services will attend to the patients. The pain visual analogue scale (VAS) will be used for assessment. A VAS score equal to or greater than 4 (moderate pain) would require assessment to be made by the Rehabilitation Services.

Assessment of exercise capacity:

1 To measure the response to exercise an exercise tolerance test will be performed: the six minute walk test (6MWT), which will be evaluated using the reference values for obese individuals. It will be conducted before starting the program and at 3 and 12 months.

Sleep habits Subjects will be reminded of the need to sleep enough hours and of keeping a regular sleep schedule. Sleep hygiene guidelines will be provided in writing.

Control group: They will be managed according to the usual recommendations: they will be given a diet and exercise plan in writing, which is the one commonly used in the Dietetics Unit, established by the Dietetics Unit according to patient age and level of activity, without any other assessment or additional visits by the Dietetics Unit. Visits to the Sleep Disorders Unit will be scheduled to coincide with the assessments at 3 and 12 months, the same as for the intervention group.

Criteria for withdrawal from the study:

  • occurrence of osteoarticular pain that prevents a patient from continuing to exercise
  • a patient's continued refusal to follow the recommended guidelines

RECRUITMENT PERIOD: Potential candidates will be selected from among patients who are being followed by their doctor or nurse for CPAP treatment. All potential candidates will be invited to participate in the study in consecutive order until the required number of patients has been reached.

MONITORING PERIOD: All patients will complete the one year of monitoring. If any adverse effects occur during the monitoring period, they will be recorded and discontinuation of the protocol will be assessed. Diet-related adverse effects are not expected as the patients will be followed very closely by the nutritionist. In the event any exercise-related osteoarticular pain should occur, the Rehabilitation Services will assess the patients and determine whether the exercise should be modified or discontinued.

ETHICAL ISSUES: The study will be conducted in accordance with the principles of the Declaration of Helsinki, as well as of the Data Protection Act (Law 15/1999). All patients will be asked to provide informed consent, in accordance with the rules of the Ethics Committee at our institution.

Since all of the patients will be receiving CPAP treatment, there should be no ethical concerns about evaluating the effectiveness of an alternative treatment that in principle is less effective than CPAP, in patients with severe OSAS.

STATISTICAL ANALYSIS:

In order to evaluate the effectiveness of a change in lifestyle (diet and exercise) in obese patients with OSAS, the investigators will first perform a descriptive analysis of the demographic variables and baseline characteristics according to the number of cases and percentages for the qualitative variables and the investigators will use measures of central tendency (mean, median) and dispersion (standard deviation and interquartile range) for the quantitative variables.

In order to answer the primary and secondary objectives of this study, the investigators will run an inferential analysis comparing data at baseline, at 3 months and at one year in the two treatment groups. Tests for independent samples will be used in every case (between the control and experimental groups). Either the chi-square test or Fisher's exact test will be used, as appropriate, to compare categorical variables and Student's T-test will be used to compare continuous variables; if the variable under study does not meet the conditions for the applicability of parametric tests, a non-parametric alternative, the Mann Whitney U test, will be used.

An estimate of treatment effect in answer to the primary and secondary endpoints will be obtained from the confidence interval (95% CI) of the difference between means and percentages, as appropriate.

Efficacy assessment will be based on an analysis of the per protocol populations (PP) and intention-to-treat (ITT), with ITT the population being the main analysis. For the population analysis using ITT, the missing data will be filled in and sensitivity analysis will be conducted if more than one method of imputation is used. The PP population will be determined in accordance with compliance with visits as well as with the diet and exercise.

A safety assessment will be made by identifying the adverse effects that are considered to be most significant due to their frequency or severity.

In all cases the significance level used will be 5% (α=0.05) with a bilateral approach.

The statistical software that will be used for the analysis will be International Business Machines Corporation (IBM) Statistical Package for the Social Sciences (SPSS) Statistics 21.

Being tested
Intensive weight loss program
Medical subject headings
Sleep Apnea, Obstructive, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intensive weight loss programBehavioural

    behavioral and dietary supplement

Study groups in NCT02832414
Study groupRoleWhat they receive
Regular programNo interventionNot described
Intensive weight loss programActive comparatorNot described
Receives: Behavioral: Intensive weight loss program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Improvement in the apnea-hypopnea index/hour: Sleep study: Standard polysomnography

    Assess whether a lifestyle change program can be effective in the medium and long term for the treatment of OSAS in obese patients with OSAS who are already receiving CPAP treatment.

    Measured: Baseline, at 3 months and 12 months.

Secondary outcomes (48)
  1. waist circumference (above the upper iliac crest): centimetre

    Measured: Baseline, at 3 months and 12 months.

  2. neck circumfarence: centimetre

    Measured: Baseline, at 3 months and 12 months.

  3. waist to hip ratio

    Measured: Baseline, at 3 months and 12 months.

  4. Measurement of visceral fat (square centimetre) by an abdominal computerized tomography (CT) scan

    Measured: Baseline, at 12 months.

  5. Carotid intima-media (C-IMT) thickness (millimeter (mm)) by ultrasound of the supra-aortic vessels, using B-mode ultrasound

    As a marker of subclinical cardiovascular disease

    Measured: Baseline, at 3 months and 12 months.

  6. Body fat composition by bioimpedance analysis (BIA 101, Akern Bioresearch, Florence, Italy).

    Measured: Baseline, at 3 months and 12 months.

  7. Measurement of health-related quality of life

    Questionnaire regarding quality of life and sleep: Functional Outcomes of Sleep Questionnaire (FOSQ), Spanish language version (Ferrer et al Med Clin (Barc 1999; 113: 250-5).

    Measured: Baseline, at 3 months and 12 months.

  8. Measurement of health-related quality of life

    Self-administered questionnaire regarding quality of life and sleep-related breathing disorders: Quebec Sleep Questionnaries (QSQ), Spanish language version (Lacasse et al Thorax 2004; 59: 494-9).

    Measured: Baseline, at 3 months and 12 months.

  9. Measurement of health-related quality of life

    Euro quality of life (EuroQol) and the Analog pain scale for the assessment of well-being with regard to the disease under study. (Masa et al AJRCCM 2004 and Sleep and Breathing 2011).

    Measured: Baseline, at 3 months and 12 months.

  10. Age (years)

    Measured: Baseline, at 3 months and 12 months.

  11. Self-perceived sleepiness

    It will be analyzed using the Epworth Sleepiness Scale (MW Johns, Sleep 1991, 14;540).

    Measured: Baseline, at 3 months and 12 months.

  12. Cardiovascular risk factors and comorbidity.

    Using general medical history questionnaire

    Measured: Baseline, at 3 months and 12 months.

  13. OSAS-related symptoms

    Measured: Baseline, at 3 months and 12 months.

  14. Testing for ketones (milligram/deciliter) using test strips

    Measured: Baseline, at 3 months and 12 months.

  15. Record of physical activity: hours of exercise will be noted daily in a journal

    Measured: Baseline, at 3 months and 12 months.

  16. Exercise capacity: 6 minute walk test (6MWT)

    Measured: Baseline, at 3 months and 12 months.

  17. Pain: VAS Analog Scale for Pain

    Measured: Baseline, at 3 months and 12 months.

  18. Blood pressure

    Measured: Baseline, at 3 months and 12 months.

  19. CPAP compliance (mean hours of usage per night as recorded by the hour meters).

    Measured: Baseline, at 3 months and 12 months.

  20. CPAP related side effects

    Measured: Baseline, at 3 months and 12 months.

  21. Hours of sleep

    Measured: Baseline, at 3 months and 12 months.

  22. Fibrinogen (gram/liter)

    Measured: Baseline, at 3 months and 12 months.

  23. Glucose (millimole/liter)

    Measured: Baseline, at 3 months and 12 months.

  24. Markers of endothelial dysfunction: Asymetric Dimethylarginine (ADMA), intercellular adhesion molecule (ICAM-1), vascular endothelial cell adhesion molecule (VCAM-1), vascular endothelial growth factor (VEGF), endothelin

    Measured: Baseline, at 3 months and 12 months.

  25. Platelet activation and markers of the fibrinolytic system: p-selectin, Soluble CD40 ligand (sCD40), Plasminogen activator inhibitor (PAI-1)

    Measured: Baseline, at 3 months and 12 months.

  26. Markers of hemodynamic dysfunction: N-terminal pro brain natriuretic peptide (NT-proBNP)

    Measured: Baseline, at 3 months and 12 months.

  27. Markers of oxidative stress: isoprostanes

    Measured: Baseline, at 3 months and 12 months.

  28. Markers of inflammation: interleukin (IL) 6, IL-8, tumor necrosis factor (TNF) alpha and TNF soluble receptors 1 and 2, adiponectin

    Measured: Baseline, at 3 months and 12 months.

  29. Gender: male, female

    Measured: Baseline

  30. Weight (kilograme)

    Measured: Baseline, at 3 months, and 12 months.

  31. Height (meter)

    Measured: Baseline, at 3 months, and 12 months.

  32. Body mass index (BMI): dividing weight in kilograms by height in meters squared

    Measured: Baseline, at 3 months, and 12 months.

  33. Start of Obesity: period of obesity

    Measured: Baseline

  34. Adherence to diet monitoring by diet questionnaries

    Measured: Baseline, at 3 months and 12 months

  35. D-dimer (microgram/liter)

    Measured: Baseline, at 3 months and 12 months

  36. Prothrombin time (PT)

    Measured: Baseline, at 3 months and 12 months

  37. Activated partial thrombopastin time (APTT)

    Measured: Baseline, at 3 months and 12 months

  38. Triglycerides (millimole/liter)

    Measured: Baseline, at 3 months and 12 months

  39. Total cholesterol (millimole/liter)

    Measured: Baseline, at 3 months and 12 months

  40. Low density lipoprotein (LDL) cholesterol (millimole/liter)

    Measured: Baseline, at 3 months and 12 months

  41. High density lipoprotein (LDL) cholesterol (millimole/liter)

    Measured: Baseline, at 3 months and 12 months

  42. Uric acid (micromole/liter)

    Measured: Baseline, at 3 months and 12 months

  43. Creatinine (micromole/liter)

    Measured: Baseline, at 3 months and 12 months

  44. C-reactive protein (milligram/liter)

    Measured: Baseline, at 3 months and 12 months

  45. Aspartate aminotransferase (microgram/liter)

    Measured: Baseline, at 3 months and 12 months

  46. Alanine aminotransferase (microgram/liter)

    Measured: Baseline, at 3 months and 12 months

  47. Thyroid-Stimulating Hormone (TSH)

    Measured: Baseline, at 3 months and 12 months

  48. Glycosylated hemoglobin

    Measured: Baseline, at 3 months and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jul 2016 (estimated)
  2. Study startJul 2016
  3. Primary completionJun 2018
  4. Study completionJun 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02832414
Sponsor's protocol ID
PR209/14
Status last verified
Aug 2019
First submitted
6 Jul 2016
Last updated
13 Aug 2019
Results posted
No

Publications

  • Lopez-Padros C, Salord N, Alves C, Vilarrasa N, Gasa M, Planas R, Montsserrat M, Virgili MN, Rodriguez C, Perez-Ramos S, Lopez-Cadena E, Ramos MI, Dorca J, Monasterio C. Effectiveness of an intensive weight-loss program for severe OSA in patients undergoing CPAP treatment: a randomized controlled trial. J Clin Sleep Med. 2020 Apr 15;16(4):503-514. doi: 10.5664/jcsm.8252.

    PubMed 32003737

Questions about this trial

What is this clinical trial studying?

A study testing Intensive weight loss program in people with Sleep Apnea, Obstructive and Obesity, run by Hospital Universitari de Bellvitge at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Improvement in the apnea-hypopnea index/hour: Sleep study: Standard polysomnography (time frame: Baseline, at 3 months and 12 months.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02832414, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in